Kazazian Asset Management Upped Biogen (BIIB) Holding By $1.41 Million; Rev Group (REVG) Shorts Up By 1.67%

January 12, 2018 - By Dolores Ford

Rev Group Incorporated (NYSE:REVG) had an increase of 1.67% in short interest. REVG’s SI was 1.55 million shares in January as released by FINRA. Its up 1.67% from 1.52M shares previously. With 467,000 avg volume, 3 days are for Rev Group Incorporated (NYSE:REVG)’s short sellers to cover REVG’s short positions. The stock decreased 0.44% or $0.14 during the last trading session, reaching $31.74. About 351,854 shares traded. REV Group, Inc. (NYSE:REVG) has 0.00% since January 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Kazazian Asset Management Llc increased Biogen Inc (BIIB) stake by 74.99% reported in 2017Q3 SEC filing. Kazazian Asset Management Llc acquired 4,500 shares as Biogen Inc (BIIB)’s stock declined 13.45%. The Kazazian Asset Management Llc holds 10,501 shares with $3.29M value, up from 6,001 last quarter. Biogen Inc now has $71.05 billion valuation. The stock increased 0.86% or $2.88 during the last trading session, reaching $335.95. About 860,250 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 12, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

REV Group, Inc. designs, manufactures, and distributes specialty vehicles in the United States, Canada, Europe, Africa, the Middle East, and internationally. The company has market cap of $2.04 billion. It operates through three divisions: Fire & Emergency, Commercial, and Recreation. It has a 63.48 P/E ratio. The Fire & Emergency segment offers a range of fire apparatus and ambulance products for municipal fire departments, EMS providers, and private fleets through dealers.

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Biogen Idec Inc. had 95 analyst reports since July 23, 2015 according to SRatingsIntel. The company was reinitiated on Tuesday, July 11 by Jefferies. The firm has “Neutral” rating by Citigroup given on Tuesday, June 7. Jefferies initiated the shares of BIIB in report on Wednesday, September 9 with “Buy” rating. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, August 17 report. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Neutral” rating by Citigroup on Monday, October 23. The rating was upgraded by Leerink Swann on Monday, November 7 to “Outperform”. The rating was downgraded by BMO Capital Markets to “Market Perform” on Friday, July 24. The rating was downgraded by Leerink Swann on Thursday, March 16 to “Market Perform”. Stifel Nicolaus maintained Biogen Inc. (NASDAQ:BIIB) rating on Tuesday, July 25. Stifel Nicolaus has “Hold” rating and $30000 target. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Monday, October 23 by SunTrust.

Since January 9, 2018, it had 0 insider buys, and 1 sale for $1.92 million activity. PANGIA ROBERT W sold $1.92 million worth of stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts